BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16025267)

  • 1. Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells.
    Fukui M; Ueno K; Suehiro Y; Hamanaka Y; Imai K; Hinoda Y
    Cancer Immunol Immunother; 2006 May; 55(5):538-46. PubMed ID: 16025267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model.
    Amano T; Kajiwara K; Yoshikawa K; Morioka J; Nomura S; Fujisawa H; Kato S; Fujii M; Fukui M; Hinoda Y; Suzuki M
    J Neurosurg; 2007 Apr; 106(4):638-45. PubMed ID: 17432716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
    Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
    Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
    Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
    Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
    Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
    Niedworok C; Kretschmer I; Röck K; Vom Dorp F; Szarvas T; Heß J; Freudenberger T; Melchior-Becker A; Rübben H; Fischer JW
    PLoS One; 2013; 8(9):e75681. PubMed ID: 24069434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas.
    Shigeishi H; Fujimoto S; Hiraoka M; Ono S; Taki M; Ohta K; Higashikawa K; Kamata N
    Int J Oncol; 2009 Jun; 34(6):1565-71. PubMed ID: 19424574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental regulation of hyaluronan-binding protein (RHAMM/IHABP) expression in early bovine embryos.
    Stojkovic M; Krebs O; Kölle S; Prelle K; Assmann V; Zakhartchenko V; Sinowatz F; Wolf E
    Biol Reprod; 2003 Jan; 68(1):60-6. PubMed ID: 12493696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
    Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
    Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
    Moran TP; Burgents JE; Long B; Ferrer I; Jaffee EM; Tisch RM; Johnston RE; Serody JS
    Vaccine; 2007 Sep; 25(36):6604-12. PubMed ID: 17675184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.